singledomain antibody sdab also known nanobody antibody fragment consisting single monomeric variable antibody domain like whole antibody able bind selectively specific antigen molecular weight kda singledomain antibodies much smaller common antibodies kda composed two heavy protein chains two light chains even smaller fab fragments kda one light chain half heavy chain singlechain variable fragments kda two variable domains one light one heavy first singledomain antibodies engineered heavychain antibodies found camelids called vhh fragments cartilaginous fishes also heavychain antibodies ignar immunoglobulin new antigen receptor singledomain antibodies called vnar fragments alternative approach split dimeric variable domains common immunoglobulin g igg humans mice monomers although research singledomain antibodies currently based heavy chain variable domains nanobodies derived light chains also shown bind specifically target camelid nanobodies shown specific antibodies cases robust easily isolated using phage panning procedure used antibodies allowing cultured vitro large concentrations smaller size single domain make antibodies easier transform bacterial cells bulk production making ideal research singledomain antibodies researched multiple pharmaceutical applications potential use treatment acute coronary syndrome cancer alzheimers singledomain antibody peptide chain amino acids long comprising one variable domain vh heavychain antibody common igg peptides similar affinity antigens whole antibodies heatresistant stable towards detergents high concentrations urea derived camelid fish antibodies less lipophilic soluble water owing complementaritydetermining region forms extended loop coloured orange ribbon diagram covering lipophilic site normally binds light contrast common antibodies two six singledomain antibodies survived temperature without losing ability bind antigens stability towards gastric acid proteases depends amino acid sequence species shown active intestine oral low absorption gut impedes development systemically active orally administered singledomain antibodies comparatively low molecular mass leads better permeability tissues short plasma halflife since eliminated unlike whole antibodies show complement system triggered cytotoxicity lack fc region camelid fish derived sdabs able bind hidden antigens accessible whole antibodies example active sites property shown result extended loop able penetrate buried singledomain antibody obtained immunization dromedaries camels llamas alpacas sharks desired antigen subsequent isolation mrna coding variable region vnar vhh heavychain antibodies large phage displayed vnar vhh single domain libraries established nurse dromedary screening techniques like phage display ribosome display help identify clones binding single domain antibodies including vnars humanized clinical alternatively singledomain antibodies made common human four process similar comprising gene libraries immunized na√Øve donors display techniques identification specific antigens problem approach binding region common igg consists two domains vh vl tend dimerize aggregate lipophilicity monomerization usually accomplished replacing lipophilic hydrophilic amino acids often results loss affinity affinity retained singledomain antibodies likewise produced e cerevisiae organisms humans occasionally produce single domain antibodies random creation stop codon light chain human singledomain antibodies targeting various tumor antigens including isolated phage display human singledomain antibodies used create immunotoxins chimeric antigen receptor car treating liver cancer blocking wnt binding domain human singledomain antibody inhibits wnt activation liver cancer singledomain antibodies allow broad range applications biotechnical well therapeutic use due small size simple production high fusion fluorescent protein nanobody generates socalled chromobody chromobodies used recognize trace targets different compartments living cells therefore increase possibilities live cell microscopy enable novel functional coupling antigfp nanobody monovalent matrix called gfpnanotrap allows isolation gfpfusion proteins interacting partners biochemical single molecule localization superresolution imaging techniques requires specific delivery fluorophores close proximity target protein due large size use antibodies coupled organic dyes often lead misleading signal owing distance fluorophore target protein fusion organic dyes antigfp nanobodies targeting gfptagged proteins allows nanometer spatial resolution minimal linkage error small size high size dividend nanobodies also benefits correlative lightelectron microscopy study without permeabilization agent cytoplasm chemically fixed cells readily accessible fluorophore tagged nanobodies small size also allows penetrate deeper volumetric samples regular antibodies high ultrastructural quality preserved tissue imaged fluorescence microscope electron microscope especially useful neuroscience research requires molecular labeling electron microscopic diagnostic biosensor applications nanobodies may used prospectively tool due small size coupled densely biosensor surfaces addition advantage targeting less accessible epitopes conformational stability also leads higher resistance surface regeneration conditions immobilizing singledomain antibodies sensor surfaces sensing human prostatespecific antigen hpsa tested nanobodies outperformed classical antibodies detecting clinical significant concentrations increase crystallization probability target molecule nanobodies used crystallization chaperones auxiliary proteins reduce conformational heterogeneity binding stabilizing subset conformational states also mask surfaces interfering crystallization extending regions form crystal singledomain antibodies tested new therapeutic tool multiple targets mice infected influenza virus subtype nanobodies directed hemaglutinin suppressed replication virus vivo reduced morbidity nanobodies targeting cell receptor binding domain virulence factors toxin toxin b clostridium difficile shown neutralize cytopathic effects fibroblasts nanobody conjugates recognizing antigen presenting cells successfully used tumor targeted antigen delivery generate strong immune orally available singledomain antibodies e coliinduced diarrhoea piglets developed successfully diseases gastrointestinal tract inflammatory bowel disease colon cancer also possible targets orally available singledomain detergentstable species targeting surface protein malassezia furfur engineered use antidandruff approach photothermal therapy nanobodies binding antigen overexpressed breast ovarian cancer cells conjugated branched gold nanoparticles see figure tumor cells destroyed photothermally using laser test caplacizumab singledomain antibody targeting von willebrand factor clinical trials prevention thrombosis patients acute coronary phase ii study examining high risk percutaneous coronary intervention started september ablynx expects nanobodies might cross barrier permeate large solid tumours easily whole antibodies would allow development drugs brain nanobodies tightly bind rbd domain spike protein betacoronaviruses including causes blocks interactions spike cell receptor recently application various single domain antibodies nanobodies prevention treatment infection various highly pathogenic human coronaviruses hphcovs reported prospects potency challenges deploying nanobodies bind neutralize akin recently one common causes nagana trypanosoma brucei brucei targeted sdabs stijlemans et al succeeded inducing effective sdabs rabbit camelus dromedarius displaying variable surface glycoprotein antigen vertebrates immune systems using phage future therapies surpass natural antibodies reaching locations currently unreachable due natural antibodies larger httpsenwikipediaorgwikisingledomainantibody